Mode of action Product Candidate or Program Indication Discovery Pre-clinical Phase 1 Phase 2 Phase 3/ Pivotal
Cancer metabolism
Tumor starvation
eryaspase /GRASPA®
Pancreatic Cancer 2L TRYbeCA-1
Triple Negative Breast Cancer 1L TRYbeCA-2
Acute Lymphoblastic Leukemia 2L NOPHO IST
Pancreatic cancer 1L  IST
erymethionase (Methionine-γ-Lyase) Solid tumors  
Immune modulation Immuno-oncology Tolerance induction TBD*  
Enzyme replacement Therapeutic Enzymes Metabolic diseases  

Arrow indicates most advanced study within an indication or program; more detail is provided in subsequent slides
* To be determined by SQZ Biotech